Jonathan Riess, MD

home / authors / jonathan-riess-md

Articles

Jonathan Wesley Riess, MD, MS, director, Thoracic Oncology, associate professor, medicine, Division of Hematology and Oncology, University of California, Davis Comprehensive Cancer Center

Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLC

August 2nd 2024

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis

Dr Riess on Advancements in Thymic Epithelial Malignancy Management

Jonathan Riess, MD

July 30th 2024

Jonathan W. Riess, MD, MS, discusses advancements, as well as unmet needs in the management of thymic malignancies.

Dr Riess on the Initial Efficacy of the IO102-IO103 Vaccine Plus Pembrolizumab in Lung Adenocarcinoma

Jonathan Riess, MD

September 25th 2023

Jonathan W. Riess, MD, MS, discusses preliminary results from a phase 2 trial of the IO102-IO103 immuno-modulating cancer vaccine plus pembrolizumab in patients with metastatic non–small cell lung cancer adenocarcinoma.

Looking Toward the Future Management of Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 16th 2022

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 16th 2022

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Novel Therapy for NSCLC With ALK Rearrangements

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 9th 2022

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Novel Therapy for NSCLC With KRAS G12C Mutation

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jonathan Riess, MD;Jessica Donington, MD, MSCR;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 9th 2022

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Heather Wakelee, MD;Alexander Spira, MD, PhD, FACP

August 2nd 2022

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jonathan Riess, MD;Jessica Donington, MD, MSCR;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

August 2nd 2022

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Selecting Therapy for Advanced NSCLC With EGFR Mutations

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather Wakelee, MD

July 26th 2022

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Neoadjuvant Strategies in Resectable Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee, MD, FASCO

July 26th 2022

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS Trials

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee

July 19th 2022

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee

July 19th 2022

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee

July 12th 2022

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee

July 12th 2022

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee, MD, FASCO

July 5th 2022

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee, MD, FASCO

July 5th 2022

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

Real-World Data and Barriers to Use of Molecular Testing in NSCLC

Benjamin P. Levy, MD;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Heather A. Wakelee, MD, FASCO

June 28th 2022

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

Optimal Molecular Testing Practices in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Jessica Donington, MD, MSCR;Jonathan Riess, MD;Alexander Spira, MD, PhD, FACP;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Heather A. Wakelee, MD, FASCO

June 28th 2022

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

Dr. Riess on the Long-Term Benefit With Immunotherapy for Lung Cancer

Jonathan Riess, MD

September 1st 2017

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

Dr. Riess on ROS1 Fusions in Lung Cancer

Jonathan Riess, MD

September 14th 2016

Jonathan Riess, MD, assistant professor of Medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses ROS1 fusions in lung cancer.